Drug Profile
Amelparib - Jeil Pharmaceutical
Alternative Names: JI-6289; JPI-289; OJP-3101Latest Information Update: 13 Oct 2021
Price :
$50
*
At a glance
- Originator Jeil Pharmaceutical
- Developer Jeil Pharmaceutical; Oncocross
- Class Anti-ischaemics; Ethers; Morpholines; Naphthyridines; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Stroke
- Preclinical Unspecified
Most Recent Events
- 07 Oct 2021 Preclinical trials in Unspecified in South Korea (unspecified route) before October 2021 (Oncocross' pipeline, October 2021)
- 25 Sep 2020 Amelparib is still in phase II trials for Stroke in South Korea (NCT03062397)
- 01 Aug 2019 Chemical structure information added